
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is a clinical-stage biotech company with a focus on developing novel therapeutics in severe eye diseases and other organs through the Wnt signaling pathway. With its lead candidate SZN-8141, Surrozen is targeting improved efficacy, longer-lasting results, and reduced injection frequency compared to current retinal therapies, which is a critical factor for potential differentiation and adoption in retinal vascular diseases. With positive preclinical results and a strong pipeline, along with a partnership with Boehringer Ingelheim, Surrozen is well-positioned for potential success in the competitive retinal disease space.
Bears say
Surrozen is a clinical-stage biotechnology company that has demonstrated promising preclinical results with its product candidate, SZN-8141, in terms of accelerating vascular regeneration and reducing avascular and pathological neovascular tuft areas in retinal vascular disease. However, the company reported a net loss of $127.5M for 1Q26 and will require substantial financing for development and commercialization. Additionally, there are still questions about the durability and long-term effectiveness of novel therapies in the retinal therapeutic space.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares